Coulter Partners was very pleased to partner recently with 2N Pharma, a biotech company developing therapeutic drugs to treat neurological disorders, to secure the appointments of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director. Coulter Partners and BioInnovation Institute have a Partnership Agreement to support BII Creation House companies as they build and develop their Boards and Executive teams.
“We are very proud and excited to welcome Alex and John to the Board,” said Preben Bruun-Nyzell, 2N Pharma’s Chief Executive Officer. “They bring decades of leadership in company building and neuroscience drug development that are vital as we continue to advance our therapeutic candidates to treat neurodegeneration. I thank the team at Coulter Partners for their professional support in achieving these high calibre appointments.”
“It gives me great pleasure to join 2N Pharma as Chair of the Board of Directors”, said Alex Leech. “I am excited to help set the agenda for this ambitious company and look forward to working with the management team to fully explore the disruptive potential of 2N’s approach to treating neurological disorders.”
“With a focus on neurodegenerative diseases, 2N is tackling some of the biggest challenges in medical science,” said John Kemp. “I am impressed by the company’s novel approach, and I look forward to applying my insights as a drug developer to guide the company at this exciting time”.
Alex Leech was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and was CEO of Zarodex Therapeutics and Camphos Therapeutics. Prior to Creabilis, he led operations at US-based pain company Solace Pharmaceuticals Inc. Alex gained his R&D experience at Pfizer and is a Venture Partner with SV Health Investors.
John Kemp is the CSO of Syndesi Therapeutics. Former roles include Head of Neuroscience Discovery at Janssen, Belgium and CEO of Evotec Neurosciences, which was spun-out from Evotec and raised a €25m Series A in 2004. Before joining Evotec, John was SVP and Head of CNS Research at Roche and he also held senior research positions in Neuroscience R&D at Merck Sharpe and Dohme. John has published over 140 peer reviewed articles, was an original member of ISI’s Most Highly Cited Researcher Database and has an h-index of 74.
About 2N Pharma
2N Pharma is a small biotech company with a big ambition: we want to develop drugs that can effectively treat neurodegenerative diseases. We have developed novel, orally administered, small molecule therapeutic drug candidates that cross the blood-brain barrier to target mitochondrial dysfunction that has been linked to disease progression in several neurodegenerative diseases. Our lead indication is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease and MND. 2N Pharma is based in Aalborg, Denmark and at the BioInnovation Institute in Copenhagen, Denmark.
For more information about 2N Pharma, please visit 2npharma.com
ChinaBio Partnering Forum (Virtual)
25 September 2023 – 26 September 2023
Top hires for VC & PE portfolio companies Q3-2022
20 October 2022
Top global hires for large-cap, mid-cap and public companies
16 November 2021
Coulter Partners secures Chief Finance Officer and Non-Executive Director for Optimapharm
02 March 2021